Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 13/20 | 0.48 |
| ▸ | NSD2 | O96028 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.39 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25037752 | 0.88 | CNR1 (0.50) | SETD2NSD2MEN1KMT2AMAPT | |
| SCHEMBL25039576 | 0.77 | SETD2 (0.53) | SETD2NSD2PLA2G7MEN1NPC1 | |
| SCHEMBL26098096 | 0.76 | SETD2 (0.47) | SETD2NSD2POLBRXFP1PLA2G7 | |
| SCHEMBL26099783 | 0.74 | NPC1 (0.60) | SETD2NSD2POLBRXFP1MEN1 | |
| SCHEMBL25039719 | 0.73 | SETD2 (0.57) | SETD2NSD2CNR1 | |
| SCHEMBL25040178 | 0.72 | SETD2 (0.59) | SETD2NSD2PLA2G7NPC1RAB9A | |
| SCHEMBL25039980 | 0.72 | CYP1A2 (0.57) | SETD2NSD2POLBMEN1KMT2A | |
| SCHEMBL21739280 | 0.72 | HRH4 (0.56) | SETD2NSD2HRH4 | |
| SCHEMBL25039711 | 0.72 | HRH4 (0.56) | SETD2NSD2HRH4 | |
| SCHEMBL21739348 | 0.71 | HRH4 (0.54) | SETD2NSD2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| EP-3837240-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112585119-A | Substituted indoles and methods of use thereof | EPIZYME股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | SETD2 947/4885NSD2 641/4885HRH4 457/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | SETD2 1006/4885NSD2 644/4885HRH4 530/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SETD2 1/4885NSD2 35/4885HRH4 4351/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SETD2 8/4885NSD2 6/4885HRH4 3748/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SETD2 3/4885NSD2 14/4885HRH4 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.